Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Lung Cancer

• Status: Unknown status
• Trial end date: 2018-08-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the safety and effectiveness of cell therapy using Precision Cell Immunotherapy to treat Advanced Lung Cancer.

Eligibility:

Individuals greater than or equal to 18 years of age and less than or equal to 65 years of age who have been diagnosed with Advanced Lung Cancer.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ningbo Cancer Hospital

Criteria

Inclusion Criteria:

1. Age 18~65 years old, male or female;

2. Life expectancy≥6 months;

3. ECOG score: 0-3;

4. Advanced Malignancies (lung cancer) were diagnosed by pathological or clinical physicians;

5. Enough venous channel, no other contraindications to the separation and collection of white blood cells;

6. Laboratory examination: white blood cell≥3 x 10*9/L, blood platelet count≥60 x10*/L,hemoglobin≥85g/L; lymphocyte count≥15%, total bilirubin≤100 mol/L; ALT and AST less than five times of the normal level; serum creatinine less than 1.5 times of the normal level；

7. Signed informed consent；

8. Women of child-bearing age must have evidence of negative pregnancy test and be willing to practice birth control after 2 weeks following the cells transfusion.

Exclusion Criteria:

1. Expected Overall survival < 6 months;

2. Patients with uncontrolled hypertension (>160/95mmHg), unstable coronary disease (uncontrolled arrhythmias, unstable angina, decompensated congestive heart failure (> Class II, NYHA), or myocardial infarction within 6 months.

3. Other serious diseases: nervous, mental disorders, immune regulatory diseases, metabolic diseases, infectious diseases, etc;

4. Other drugs, or other biological treatment,chemotherapy or radiotherapy are performed within a month.

5. Unable or unwilling to provide informed consent, or fail to comply with the test requirements.